E
Aimia Inc. AIM.TO
TSX
Recommendation
Sell
Prev Close
$2.34
Volume
--
Avg Vol (90D)
32,776
Market Cap
$154.93M
Dividend & Yield
--
52-Week Range
$2.22 - $3.10
P/E (TTM)
--
EPS (TTM)
-$0.7518
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
2/28/2025 - Globe Newswire
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
2/26/2025 - Globe Newswire
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
2/26/2025 - Globe Newswire
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
2/25/2025 - Globe Newswire
AIM ImmunoTech Releases Virtual Investor What This Means Segment
2/11/2025 - Globe Newswire
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
2/11/2025 - Globe Newswire
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen and AstraZeneca's FluMist to address the recent avian influenza outbreaks
2/7/2025 - Globe Newswire
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
2/5/2025 - Globe Newswire
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
1/23/2025 - Globe Newswire
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
1/22/2025 - Globe Newswire
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
1/15/2025 - Globe Newswire
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
12/17/2024 - Globe Newswire
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
12/12/2024 - Globe Newswire
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
12/6/2024 - Globe Newswire
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
11/19/2024 - Globe Newswire
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/15/2024 - Globe Newswire
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
11/6/2024 - Globe Newswire
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
10/9/2024 - Globe Newswire
AIM ImmunoTech Granted U.S. Patent for Ampligen for the Treatment of Endometriosis
10/3/2024 - Globe Newswire
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
9/30/2024 - Globe Newswire
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
9/27/2024 - Globe Newswire
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
9/19/2024 - Globe Newswire
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential to Improve the Post-COVID Condition of Fatigue
9/11/2024 - Globe Newswire
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
8/20/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$321.31M
EBITDA (TTM)
-$9.17M
EBIT (TTM)
-$34.83M
Net Income (TTM)
-$58.37M
Balance Sheet
Total Assets (Q)
$721.49M
Total Debt (Q)
$151.60M
Total Liabilities (Q)
$307.41M
Book Value Per Share (Q)
$4.16
Cash Flow
Cash from Operations (TTM)
-$14.17M
Cash from Investing (TTM)
$44.36M
Cash from Financing (TTM)
$27.58M
Net Change in Cash (TTM)
$57.26M
Filings
Filing Date
Friday, November 8, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
0.46
7-Day Total Return
5.04%
30-Day Total Return
-3.47%
60-Day Total Return
-9.09%
90-Day Total Return
-1.57%
Year to Date Total Return
-7.41%
1-Year Total Return
-15.82%
2-Year Total Return
-39.76%
3-Year Total Return
-47.81%
5-Year Total Return
-12.28%
52-week Low
Nov 25, 2024 - $2.22
52-week High
Jun 04, 2024 - $3.10
Valuation
Market Cap
$154.93M - Micro Cap
Enterprise Value
$225.02M
Price/Sales (TTM)
0.71
Price/Book (Q)
0.56
Dividends and Shares
Shares Outstanding
96.90M
Dividend Per Share (Most Recent)
$0.20
Dividend Per Share (TTM)
--
Corporate Info
Website
www.aimia.com
Phone Number
647-948-8758
Address
1 University Avenue
Toronto, ON M5J 2P1
Country
Canada
Year Founded
2008
Business Description
Sector
Materials
Industry
Materials
Aimia Inc. invests in public and private companies. It operates through Bozzetto, Cortland International, and Holdings segments. The company, through its long-term investments, provides specialty... more
Weiss Ratings